Genetic biomarker IDs patients with increased risk for heart damage by anthracycline chemo

Among women with breast cancer who received a type of chemotherapy called an anthracycline, those who had a certain genetic biomarker had a significantly increased risk for having anthracycline-induced congestive heart failure.